Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.58 |
| ▸ | TP53 | P04637 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | SCD | O00767 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13391952 | 0.93 | MAPT (0.61) | MAPTTP53SMN1; SMN2POLBLMNA | |
| SCHEMBL12422197 | 0.91 | MAPT (0.54) | MAPTTP53SMN1; SMN2POLBLMNA | |
| SCHEMBL2195695 | 0.89 | RAB9A (0.55) | MAPTTP53SMN1; SMN2POLBNPC1 | |
| SCHEMBL2194080 | 0.88 | MAPT (0.54) | MAPTTP53SMN1; SMN2POLBLMNA | |
| SCHEMBL12421998 | 0.85 | MAPT (0.62) | MAPTTP53SMN1; SMN2POLBLMNA | |
| SCHEMBL24711222 | 0.81 | MAPT (0.67) | MAPTTP53SMN1; SMN2POLBLMNA | |
| SCHEMBL12421990 | 0.80 | MAPT (0.62) | MAPTTP53SMN1; SMN2POLBLMNA | |
| SCHEMBL2193173 | 0.80 | NPC1 (0.55) | MAPTTP53LMNANPC1RAB9A | |
| SCHEMBL2192719 | 0.80 | NPC1 (0.54) | MAPTTP53NPC1RAB9AMEN1 | |
| SCHEMBL12509015 | 0.79 | NPC1 (0.53) | MAPTTP53NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2338059-B1 | Ligands for aggregated tau molecules | WISTA LAB LTD (SG) | 2015-04-08 | — | — | EP | disclosed |
| US-8895313-B2 | Ligands for aggregated tau molecules | WISTA LABORATORIES LTD. (SG) | 2014-11-25 | — | — | US | disclosed |
| US-8895313-B2 | Ligands for aggregated tau molecules | WISTA LABORATORIES LTD. (SG) | 2014-11-25 | — | — | US | disclosed |
| CN-102224423-A | Ligands for aggregated tau molecules | WISTA LAB LTD | 2011-10-19 | — | — | CN | disclosed |
| US-20110171739-A1 | LIGANDS FOR AGGREGATED TAU MOLECULES | WISTA LABORATORIES LTD. | 2011-07-14 | — | — | US | disclosed |
| US-20110171739-A1 | LIGANDS FOR AGGREGATED TAU MOLECULES | WISTA LABORATORIES LTD. | 2011-07-14 | — | — | US | disclosed |
| EP-2338059-A1 | LIGANDS FOR AGGREGATED TAU MOLECULES | Wista Laboratories Ltd. (SG) | 2011-06-29 | — | — | EP | disclosed |
| WO-2010034982-A1 | LIGANDS FOR AGGREGATED TAU MOLECULES | WISTA LABORATORIES LTD. (SG) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010034982-A1 | LIGANDS FOR AGGREGATED TAU MOLECULES | WISTA LABORATORIES LTD. (SG) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171739-A1 | LIGANDS FOR AGGREGATED TAU MOLECULES | MAPT, PRNP, MAP4 | MAPT 1/4885TP53 94/4885SMN1; SMN2 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.